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Edited by Vladimir SkulachevAbstract The FK506-binding protein 38 (FKBP38) is a pro-
apoptotic regulator of Bcl-2 in neuroblastoma cells. Hsp90
inhibits the pro-apoptotic FKBP38/CaM/Ca2+ complex and thus
prevents interactions between FKBP38 and Bcl-2. Here we show
that Hsp90 increases cell survival rates of neuroblastoma cells
after apoptosis induction. Depletion of FKBP38 by short inter-
ference RNA signiﬁcantly decreased the anti-apoptotic eﬀect of
Hsp90 expression. In addition, the inﬂuence of high cellular
Hsp90 levels was only observed in post-stimulation apoptosis
that is sensitive to selective FKBP38 active site inhibition. Sim-
ilar anti-apoptotic eﬀects in neuroblastoma cells were observed
after stimulation of endogenous Hsp90 expression. Hence, the
inhibition of FKBP38 by Hsp90 participates in programmed cell
death control of neuroblastoma cells.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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FKBP38 is a CaM/Ca2+-regulated member of the FK506-
binding protein (FKBP) family of peptidyl–prolyl cis/trans
isomerases (PPIases, EC 5.2.1.8). PPIases assist protein folding
by catalyzing the slow interconversion of cis and trans isomers
of peptidyl–prolyl bonds in polypeptide chains, which is in-
volved in de novo protein folding and the regulation of native
proteins in signal transduction pathways [1,2]. FKBP38, in con-
trast to other human FKBP, was found to exhibit PPIase activ-
ity only in association with CaM/Ca2+ and thus regulated by
the Ca2+-sensor protein at high cellular Ca2+ concentrations [3].
The enzymatic activity of FKBP38 promotes controlled cell
death of neuroblastoma cells by inhibiting the anti-apoptotic
activity of Bcl-2 [3,4]. Low molecular weight inhibitors of
FKBP38 and FKBP38 short interference RNA (siRNA) con-
structs substantially increased the survival rates of neuroblas-
toma cells during post-stimulation apoptosis. The FKBP38Abbreviations: FKBP, FK506-binding protein; PPIase, peptidyl–prolyl
cis/trans isomerases; siRNA, short interference RNA; TPR, tetratric-
opeptide repeat; IAA, iodoacetic acid
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doi:10.1016/j.febslet.2007.11.037inhibitor DM-CHX showed in addition neuroprotective and
neuroregenerative eﬀects in endothelin-1 induced middle cere-
bral artery occlusion (eMCAO) stroke model in the rat brain
[5]. FKBP38 activity inﬂuences controlled cell death also in
other cell types. Thus, the interaction between FKBP38 and
the Hepatitis C virus protein NS5A has an anti-apoptotic eﬀect
in hepatoma cells [6,7]. Mouse FKBP38 is involved in the reg-
ulation of neuronal development by inhibiting sonic hedgehog
signaling [8]. FKBP38 displayed furthermore anti-tumor ef-
fects by the regulation of anti-invasive syndecan 1 gene expres-
sion and suppression of the proinvasive MMP9 gene [9] and
inﬂuences cell size regulation [10]. Recently human FKBP38
was also identiﬁed to interact with prolyl-4-hydroxylase 2
(PHD2), thereby inﬂuencing the protein stability of the hypox-
ia-inducible transcription factors-regulating PHD2 [11].
FKBP38 contains a catalytic domain and a tetratricopeptide
repeat (TPR) domain in its C-terminal region. FKBPs with sim-
ilar domain composition are involved in homologous chromo-
some pairing during male meiosis [12], steroid hormone
receptor signaling [13–15] and cellular dioxin response [16]. In
these processes the TPR domains mediate interactions between
Hsp90 and the diﬀerent FKBPs. Hsp90 on the other hand binds
the diﬀerent TPR-containing FKBPs via the 12 kDa C-terminal
(C90) domain [16,17]. The active form of FKBP38 interacts
also via its TPR domain with the C90 domain of Hsp90 [18].
The formation of the complex between FKBP38/CaM/Ca2+
and Hsp90, however, inhibits the catalytic activity of FKBP38
and thus prevents interaction with Bcl-2 [18].
Hsp90 exists in two isoforms (Hsp90a and Hsp90b) which
share about 86% identity in their amino acid sequences.
Hsp90 usually forms dimers in the cell [19–21]. The dimeriza-
tion is mediated by the C90 domain with a dissociation con-
stant in the low nanomolar range [22,23].
Hsp90 was previously shown to be involved in the regulation
of programmed cell death [24,25]. The heat shock protein reg-
ulates, for instance, the apoptosis inhibitor survivin [26].
Hsp90 facilitates also the phosphorylation of ASK1 by Akt
[27]. Furthermore Hsp90 has a function in cell survival by pro-
tecting proteins from degradation [28].
Here we show that the interaction between the CaM-depen-
dent PPIase FKBP38 and Hsp90 increases the cell survival
rates of neuroblastoma cells in post-stimulation apoptosis,
by inhibition of the controlled cell death.2. Materials and methods
The FKBP38 antibody was an aﬃnity puriﬁed section 4 polyclonal
antibody from rabbit against the puriﬁed FKBP38 domain (aminoblished by Elsevier B.V. All rights reserved.
5710 F. Erdmann et al. / FEBS Letters 581 (2007) 5709–5714acids 1-165). Additional antibodies used: polyclonal rabbit anti-actin
(Sigma), monoclonal hamster anti-Bcl-2 (Pharmingen), monoclonal
rat anti-Hsp90 (Stress Gene). Low molecular weight substances were
synthesized according to standard procedures [29] and characterized
by ESI mass spectrometry. Iodoacetic acid (IAA, ICH2CO2H) was
purchased from Sigma–Aldrich.
2.1. Cell culture
To test the eﬀect of IAA-induced protein expression and FKBP38
inhibitors the neuroblastoma cell line SH-SY5Y (DSMZ, Braun-
schweig, Germany) was used. Cells were cultured in DMEM (Bio-
chrom, Berlin, Germany) supplemented with 2 mM L-glutamine and
10% (v/v) heat-inactivated FCS in a humidiﬁed incubator at 37 C in
10% (v/v) CO2. SH-SY5Y cells were seeded at 5 · 106 cells/ml in 6-well
plates.
2.2. Induction of apoptosis
The cells were preincubated with various concentrations of IAA and
GPI1046 for 20 min at 37 C before apoptotic stimuli were applied.
Stock solutions of GPI1046 in ethanol were added to a ﬁnal concentra-
tion of 0.5% (v/v) ethanol in each sample. IAA was dissolved in PBS.
After induction of apoptosis, cells were grown for 16 h at 37 C and
10% CO2.
2.3. Apoptosis assay
Cells were analysed after 16 h by phase contrast microscopy at 400-
fold magniﬁcation. Survival rates of SH-SY5Y cells treated with apop-
totic stimuli and various concentrations of IAA, and GPI1046 were
determined by ViaCount assay using a Guava PCA instrument
(Guava Technologies, Hayward, CA). The ViaCount assay uses a
combination of two nucleic acid dyes in order to distinguish viable
from damaged cells and simultaneously assess the apoptotic cell frac-
tion. The assay was performed according to the manufacturer’s
instructions. The data were statistically analyzed by non-paired Stu-
dent’s tests with Graphpad software. Data are represented as
means ± S.D. Statistical signiﬁcance was accepted at the level of 0.05
of probability.
2.4. Depletion of Hsp90 and FKBP38 by siRNA
For depletion of Hsp90 the transient transfection with two siRNA-
Hsp90 pairs was chosen. The siRNAs were published previously [30]
and synthesized by MWG Biotech (Ebersberg, Germany). The target
sequences for the siRNAs were: Hsp90a, 5 0-CCCAGUUGAUGU-
CAU UGAUCAUCAA-3 0; Hsp90b: 5 0-GGCAGAGGAAGA-
GAAAGGUGAGAAA-3 0; and a scrambled siRNA as control. All
siRNAs were transfected into SH-SY5Y cells using electroporation
procedure (Amaxa, Cologne, Germany). The reduction of the cellular
Hsp90 level by siRNA was tested by Western blotting, and compared
with cells containing the scrambled siRNA. Depletion of FKBP38 in
SH-SY5Y using siRNA technique was performed as previously de-
scribed [3].3. Results and discussion
3.1. Increased Hsp90 levels inhibit FKBP38-dependent apoptosis
in neuroblastoma cells
Several FKBPs interact via their TPR domain with the C90
domain of Hsp90 [13,17,22,31,32]. In contrast to other human
FKBPs, only the catalytically active form of FKBP38 interacts
with Hsp90 [18]. In the resulting Hsp90/FKBP38/CaM/Ca2+
complex the PPIase activity of FKBP38 is inhibited. Since
FKBP38 activity participates in apoptosis regulation of neuro-
blastoma cells, we tested the eﬀect of altered Hsp90 levels on
post-stimulation apoptosis. To this end, we introduced
Hsp90 siRNA constructs to deplete endogenous Hsp90 in
SH-SY5Y neuroblastoma cells and transfected neuroblastoma
cells with a pcDNA3 Hsp90 construct to increase the cellular
Hsp90 concentration. In cells containing the pcDNA3 Hsp90
construct the cellular Hsp90 concentration was increased byabout 30%, whereas Hsp90 siRNA decreased the Hsp90 level
by about 60% of the control (Fig. 1A). The observed Hsp90
levels are similar to previously reported results of Hsp90
expression with transfected vectors in human cell lines [33].
Etoposide-induced apoptosis decreased the viability of SH-
SY5Y cells to about 10% compared to untreated cells
(Fig. 1B). SH-SY5Y cells with increased Hsp90 levels showed
23% more viable cells after etoposide-induced apoptosis,
whereas Hsp90-depleted neuroblastoma cells showed reduced
cell survival rates. Therefore high levels of Hsp90 can protect
neuroblastoma cells against apoptosis induced by etoposide.
In order to identify the inﬂuence of Hsp90 on FKBP38-
dependent apoptosis, we depleted endogenous FKBP38 using
a FKBP38 siRNA construct (Fig. 1C). In order to compare
the eﬀects of diﬀerent Hsp90 expression levels despite the
anti-apoptotic eﬀect of FKBP38 siRNA on post-stimulation
apoptosis, we displayed the results as n-fold of the mock
transfected control. In FKBP38-depleted cells the anti-apop-
totic eﬀect of increased Hsp90 levels was signiﬁcantly lower
than in cells transfected with control siRNA after apoptosis
induction with etoposide (Fig. 1D). The results show only a
2.1-fold increase of the viable cell population in presence of
FKBP38 siRNA compared to a 3.5-fold increase in the ab-
sence of FKBP38 siRNA. In contrast, the eﬀect of Hsp90
siRNA did not diﬀer in the experiments either in presence
or absence of FKBP38 siRNA. These results demonstrate
an inhibitory inﬂuence of increased Hsp90 levels on
FKBP38-dependent apoptosis. Thus, the Hsp90-mediated
inhibition of FKBP38 activity and interaction with Bcl-2 in-
creases the cell survival in post-stimulation apoptosis. How-
ever, FKBP38 activity is not inﬂuenced at low Hsp90
concentration, which is likely caused by competition with
other Hsp90-binding partners. For instance, FKBP51,
FKBP52, Cyp40 or Hop might compete with FKBP38 for
Hsp90 binding, since these proteins feature also TPR do-
mains that bind Hsp90 with similar or higher aﬃnity than
FKBP38 [34,35]. An involvement of Hsp90 in programmed
cell death was shown previously [36–40]. Even a moderate
increase of the Hsp90 level by 20% eﬀected signiﬁcantly
the cell survival of human monoblastoid cells following
cycloheximid- and tumor necrosis factor a-treatment [41].
Furthermore, Hsp90 was already shown to participate in
the regulation of apoptosis that can be linked to Bcl-2-
dependent pathways and the co-administration of apoptotic
stimuli and Hsp90 inhibitors potentiates the level of apopto-
sis compared to results in the absence of Hsp90 inhibitors
[24,38,42,43]. In addition to these functions, Hsp90 inhibits
at high concentrations FKBP38-dependent apoptosis in neu-
roblastoma cells.3.2. IAA-induced Hsp90 expression decreases FKBP38-
dependent apoptosis
Next, we were interested to analyze the eﬀect of stimulated
expression of endogenous Hsp90. According to a previous re-
port 2–200 nM iodoacetate (IAA) increase Hsp90 and Bcl-2
expression and thus protect hippocampal neurons against cell
death [44].
First, we examined whether Bcl-2 and Hsp90 levels were
aﬀected by 50–200 nM IAA. Western blot analysis of the cell
lysates of SH-SY5Y cells cultured for 6 h in the presence of
diﬀerent IAA concentrations using antibodies against Hsp90,
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Fig. 1. Hsp90 expression protects SH-SY5Y cells from apoptosis. (A)
SH-SY5Y cells transfected with either Hsp90 siRNA or pcDNA3-
Hsp90 construct were harvested, boiled in sample buﬀer and subjected
to SDS–PAGE. Subsequently the samples were analyzed by Western
blot using anti-Hsp90 and anti-b-actin antibodies and compared with
untransfected SH-SY5Y cell lysates (control). (B) Survival rates of SH-
SY5Y cells that were either transfected with pcDNA-Hsp90 construct
or Hsp90 siRNA and treated with 50 lM etoposide were determined
using Guava viability assay with a Guava personal cell analyzer. The
cell viability rates were compared to untreated neuroblastoma cells.
SH-SY5Y cells transfected without Hsp90 siRNA or pcDNA3-Hsp90
F. Erdmann et al. / FEBS Letters 581 (2007) 5709–5714 5711Bcl-2, FKBP38 and b-actin revealed that the cellular concen-
trations of Hsp90 and Bcl-2 were elevated (Fig. 2A). The
Bcl-2 protein level was increased moderately, leveling oﬀ to
about 130% of the control at IAA concentrations of 100 nM
(Fig. 2B). Higher IAA concentrations did not further increase
the cellular Bcl-2 concentration. Hsp90 expression, in contrast,
was increased in a concentration-dependent manner resulting
in proteins levels of about 225% of the control at 200 nM
IAA. The FKBP38 concentration was not aﬀected by IAA
administration.
We then investigated the eﬀect of IAA-induced Hsp90 and
Bcl-2 expression on the viability of neuroblastoma cells in
post-stimulation apoptosis. To this end, we treated IAA prein-
cubated neuroblastoma cells with etoposide to induce apopto-
sis. IAA administration increased the survival rates of
etoposide-challenged SH-SY5Y cells in a concentration-depen-
dent manner signiﬁcantly to about the 1.4-fold of untreated
control, similar to the anti-apoptotic eﬀect of Hsp90 expres-
sion in cells transfected with a pcDNA3 Hsp90 construct (Figs.
2 and 1B). Moreover, IAA increased the viability rates of cam-
ptothecin-treated SH-SY5Y cells to the 1.3-fold of control.
The increase of cell survival rates after apoptosis induction
by both stimuli was dependent on the IAA concentration.
Noteworthy, apoptosis induced by either etoposide or campto-
thecin is sensitive to active site inhibitors of FKBP38 and
FKBP38 depletion by FKBP38 siRNA [3]. The eﬀect of in-
creased Bcl-2 levels does not correlate with the concentration
dependent anti-apoptotic eﬀect of IAA administration. How-
ever, elevated levels of Hsp90 and Bcl-2 both shift the equilib-
rium between Bcl-2/FKBP38/CaM/Ca2+ and Bcl-2 towards the
free Bcl-2 form. Interestingly, the expression of both proteins
was reported to be up-regulated in concert in the presence of
diﬀerent exogenic stimuli [40,44].
In a reference experiment, IAA application did not increase
the survival rate of SH-SY5Y cells after staurosporin-induced
apoptosis, which was also shown to be insensitive to FKBP38
inhibition. Thus, anti-apoptotic eﬀects of increased Hsp90
expression were only detected after apoptosis induction with
stimuli, which induce cell death pathways involving FKBP38
activity.
3.3. The active site inhibitor GPI1046 and Hsp90 commonly
target FKBP38 activity
In order to assess whether elevated Hsp90 concentrations
inside the cell target exclusively FKBP38 activity, we applied
the FKBP38 inhibitor GPI1046. Thus, the cell viability of
neuroblastoma cells stimulated to apoptosis by etoposide,N 
served as control. Data were statistically analyzed by a non-paired
Student’s t-test with Graphpad software. Data are represented as
means ± S.D. from four replicates. *P 6 0.05. (C) SH-SY5Y cells were
transfected with either FKBP38 siRNA or a random siRNA construct
(control). Subsequently the cells were harvested, subjected to SDS–
PAGE and analyzed by Western blot using anti-FKBP38 and anti-b-
actin antibodies. (D) Viability of SH-SY5Y cells after treatment with
50 lM etoposide are displayed as n-fold compared to mock transfected
cells and were determined using Guava viability assay with a Guava
personal cell analyzer. The cells did either contain control siRNA
(black bars) or FKBP38 siRNA (grey bars). In addition the cells were
transfected with pcDNA-Hsp90 construct, Hsp90 siRNA or the
corresponding controls. Data were statistically analyzed by a non-
paired Student’s t-test. Data are represented as means ± S.D. from
four replicates. *P < 0.05.
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Fig. 3. GPI1046 and IAA target the same pathway of apoptosis
regulation in neuroblastoma cells. The viability of SH-SY5Y cells was
analyzed after treatment with 50 lM etoposide (black bars), 5 lM
camptothecin (light grey bars) and 100 nM staurosporin (dark grey
bars) in the presence and absence of 200 nM IAA and 5 lM GPI1046
using Guava viability assay with a Guava personal cell analyzer. Data
were statistically analyzed by a non-paired Student’s t-test. Data are
represented as means ± S.D. from four replicates. *P < 0.05.
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Fig. 2. IAA administration has anti-apoptotic eﬀects on neuroblas-
toma cells. (A) Western blot expression analysis of selected neuro-
blastoma cell proteins in dependence to diﬀerent IAA concentrations.
SH-SY5Y cells were driven into apoptosis by preincubation with either
50 lM etoposide, 5 lM camptothecin or 100 nM staurosporin. Cells
grown for 6 h in presence of 0–200 nM IAA were washed, harvested,
and lysed. The crude cell lysate was subjected to SDS–PAGE and
blotted for subsequent analysis with Hsp90, Bcl-2 and FKBP38
antibodies. b-actin was used as control. (B) The detected protein levels
were quantiﬁed by ChemiCapt software (PeqLab). The protein levels
in relation to concentrations detected in untreated cells are displayed in
the lower diagram for Hsp90 (dark grey bars), Bcl-2 (light grey bars)
and FKBP38 (black bars). The ﬁgure shows only results obtained with
samples treated with etoposide. However, samples treated with other
apoptotic stimuli showed similar results. The presented data are shown
in means ± S.D. of independent triplicates. (C) Survival rates of SH-
SY5Y cells treated with 50 lM etoposide (black bars), 100 nM
staurosporin (dark grey bars) and 5 lM camptothecin (light grey
bars) at various concentrations of IAA were determined using Guava
viability assay with a Guava personal cell analyzer. The data are
presented as means ± S.D. of three independent experiments.
5712 F. Erdmann et al. / FEBS Letters 581 (2007) 5709–5714camptothecin or staurosporin was assayed either in the pres-
ence or absence of 1 lM GPI1046 and 200 nM IAA (Fig. 3).
Both, direct FKBP38 inhibition by GPI1046 and elevated
Hsp90 concentrations increased the viability of neuroblastoma
cells in etoposide- and camptothecin-induced apoptosis indi-
vidually, as previously observed. In presence of both,
GPI1046 and IAA, the cell survival rates are further increased
to about 76% and 68% after apoptosis stimulation by etopo-
side and camptothecin, respectively. Therefore Hsp90 prevents
apoptosis not only by inhibiting FKBP38 activity, which is in
agreement with previously published data [24,25]. However, the
Hsp90-mediated FKBP38 inhibition plays also an important
role in the apoptosis regulation of neuroblastoma cells, as
demonstrated by the use of FKBP38 siRNA (Fig. 1D).
Since FKBP38/CaM/Ca2+ interacts with Hsp90 (i) inhibiting
the activity of FKBP38 and (ii) preventing interactions be-
tween FKBP38 and Bcl-2, our results suggest that elevated
Hsp90 concentrations inhibit FKBP38 and thus increase the
cell survival rates of neuroblastoma cells in post-stimulation
apoptosis. Therefore the Hsp90-mediated disruption of Bcl-2/
FKBP38/CaM/Ca2+ complexes is similar to the eﬀect observed
for the Hepatitis C virus NS5A protein that interacts with
FKBP38 [7].4. Conclusion
Hsp90 inhibits the pro-apoptotic activity of FKBP38/CaM/
Ca2+, as shown by increased Hsp90 expression and siRNA-
mediated Hsp90 depletion. In neuroblastoma cells transfected
with FKBP38 siRNA the anti-apoptotic eﬀect of Hsp90 is sig-
niﬁcantly reduced. Furthermore, IAA-stimulated Hsp90
expression increased the cell survival of neuroblastoma cells
only in FKBP38-dependent apoptosis.
F. Erdmann et al. / FEBS Letters 581 (2007) 5709–5714 5713Along with the fact that Hsp90 inhibits the activity of
FKBP38/CaM/Ca2+ these results introduce Hsp90 as a cellular
regulator of FKBP38. The formation of the Hsp90/FKBP38/
CaM/Ca2+ complex restores Bcl-2 binding capacity for its cel-
lular interaction partners and thus prevents apoptosis of neu-
ronal cells. Hence, Hsp90 is an endogenous inhibitor of
FKBP38 that increases cell survival rates of neuroblastoma
cells in post-stimulation apoptosis.
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